LRVHealth

Day-to-day investment decisions are managed by Tripp Peake, Keith Figlioli, and Josh Flum, all Managing Partners. Peake has been the public face of the firm since its 2015 spinout from Long River Ventures, where he was also a partner. The investment committee blends the partnership team with leadership from its strategic health system LPs, ensuring clinical and operational veto power from the end-users who constitute the firm’s primary customer base.

The health systems are limited partners in the fund, not clients of a separate services business. That means the providers have a direct economic interest in the portfolio’s success and participate in diligence, product design, and early adoption. LRVHealth formally launched this model with a consortium that includes Intermountain Healthcare, Northwell Health, and Providence, creating a captive commercialization channel for portfolio companies.

LRVHealth invests from seed to growth equity, with a heavy concentration in Series A and B rounds where a company is ready for initial enterprise deployment within a hospital setting. The firm also makes selective later-stage investments when an existing portfolio company or LP partner requires growth capital to scale within a health-system environment.

LRVHealth acts as both a lead and co-investor depending on the round. In early-stage companies where its health-system network provides the most value, the firm often leads or co-leads. In larger growth rounds, it typically syndicates alongside traditional venture and growth-equity partners, bringing the provider-consortium angle as a strategic component to the syndicate.

LRVHealth is neither. It is structured as a private equity fund manager with a strategic limited partner base composed entirely of healthcare providers. This hybrid model makes it function like corporate venture capital, but with the pooled resourcing and return obligations of a traditional financial sponsor, giving it a distinct governance structure uncommon in healthcare investing.

The firm focuses strictly on healthcare, and within that, it avoids pure life sciences, biotech, and pharmaceutical discovery. LRVHealth targets only healthcare IT, digital health, care delivery services, and tech-enabled payer/provider tools — areas where its provider LPs can serve as first customers and operational validators, which pharma drug development does not fit.

A meaningful portion of LRVHealth’s deal flow reaches the firm through clinical and operational leaders at its LP health systems who identify internal pain points and scout for vendors. Rather than cold-sourcing from the market, the firm effectively operates a distributed research team of thousands of clinicians and administrators who surface problems and potential solutions from inside the enterprise.